Clinical Report: Investigating the Impact of Epstein-Barr Virus on NK/T Cell Lymphoproliferative Disorders

Overview

This review discusses the molecular mechanisms of Epstein-Barr virus (EBV) infection and its role in T/NK cell lymphoproliferative disorders. It highlights the aggressive nature of these disorders.

Background

Epstein-Barr virus (EBV) is a prevalent lymphotropic virus associated with various lymphoproliferative disorders, particularly those involving T and NK cells. Understanding the molecular basis of EBV's role in these diseases is crucial for developing targeted therapies. The heterogeneity of EBV-related disorders necessitates a nuanced approach to diagnosis and treatment.

Data Highlights

No numerical data or trial data is provided in the source material.

Key Findings

• EBV can lead to a spectrum of T/NK cell lymphoproliferative disorders, from chronic inflammatory conditions to aggressive lymphomas.
• Key viral proteins such as LMP1, LMP2A, and EBNA1 play significant roles in EBV pathogenesis and immune evasion.
• EBV-positive T/NK cell disorders should not be viewed as a linear progression from infection to malignancy.
• Novel molecular biomarkers and targeted therapeutic strategies are being developed for EBV-related diseases.
• Personalized medicine and AI-assisted decision-making are proposed for the treatment of EBV-related disorders.

Clinical Implications

Clinicians should consider the aggressive nature of EBV-related T/NK cell disorders when diagnosing and treating patients.

Conclusion

The review emphasizes the complexity of EBV's role in T/NK cell lymphoproliferative disorders and the need for ongoing research into effective treatment strategies.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Epstein-Barr virus associated diseases: Immune alterations and targeted approaches
2. Frontiers in Immunology, 2026 -- Editorial: EBV strategies to counteract the immune response
3. Blood Cancer Journal, 2026 -- Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies
4. npj Digital Medicine, 2025 -- Development and validation of a predictive model for extranodal natural killer/T-cell lymphoma
5. WHO Classification, 2022 -- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia
6. ESMO-EHA Clinical Practice Guideline, 2023 -- Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up
7. BMC Cancer, 2025 -- Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis
8. PubMed, 2023 -- Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study
9. PMC, 2023 -- Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications
10. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia
11. Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up - PMC
12. Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis | BMC Cancer | Springer Nature Link
13. Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study - PubMed
14. Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications - PMC